Immunosuppression in Pediatric Kidney Transplantation

Comprehensive Pediatric Nephrology

Volumn , Issue , 2008, Pages 905-929

  Tönshoff, Burkhard ^a   Melk, Anette ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Center for Pediatrics and Adolescent Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449417150     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04883-5.50065-9     Document Type: Chapter

References (81)

1. Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta-analysis. J Am Soc Nephrol 1997, 8:1771-1777.
2. The NAPRTCS 2006 Annual Report.. https://web.emmes.com/study/ped/index.htm.
3. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplant 1999, 67:1011-1018.
4. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplant 2004, 78:136-141.
5. Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: A single-center report. Transplant 2005, 79:958-963.
6. Niaudet P, Jean G, Broyer M, Chatenoud L Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993, 7:263-267.
7. Benfield MR, Tejani A, Harmon WE, McDonald R, Stablein DM, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005, 9:282-292. for the CCTPT Study Group.
8. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplant 2004, 77:166-176.
9. Novartis 6 Oct. 2000 "Dear Healthcare Provider" letter.
10. Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006, 6:1666-1672.
11. Tönshoff B, Offner G, Höcker B, Pape L, Rascher W, et al. A multicenter, placebo-controlled trial evaluating the efficacy and safety of basiliximab (Simulect) in combination with CsA, MMF and steroids in pediatric renal allograft recipients: 12 months results. Pediatr Nephrol 2006, 21:1513.
12. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967-1977. for the Thymoglobulin Induction Study Group.
13. Al Najjar A, Etienne I, Le Pogamp P, Bridoux F, Le Meur Y, et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006, 38:2298-2299.
14. Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplant 2005, 80:765-774.
15. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, et al. Randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplant 2005, 80:457-465.
16. Morris PJ, Russell NK Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplant 2006, 81:1361-1367.
17. Bartosh SM, Knechtle SJ, Sollinger HW Campath-1H use in pediatric renal transplantation. Am J Transplant 2005, 5:1569-1573.
18. Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006, 148:813-818.
19. Dharnidharka VR, Stevens G Risk for post-transplant lymphopro-liferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005, 9:622-626.
20. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplant 2006, 81:1227-1233.
21. Franchimont D Overview of the actions of glucocorticoids on the immune response: A good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NYAcad Sci 2004, 1024:124-137.
22. Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplant 2000, 70:760-764.
23. Töenshoff B, Hoecker B, Weber LT Steroid withdrawal in pediatric and adult renal transplant recipients. Pediatr Nephrol 2005, 20:409-417.
24. Opelz G, Dohler B, Laux G Collaborative Transplant Study: Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005, 5:720-728.
25. Hoecker B, John U, Plank C, Wuehl E, Weber LT, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: Results after four years. Transplant 2004, 78:228-234.
26. Jungraithmayr T, Staskewitz A, Kirste G, Boswald M, Bulla M, et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: Results after three years. Transplant 2003, 75:454-461. for the German Pediatric Renal Transplantation Study Group.
27. Vidhun JR, Sarwal MM Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005, 20:418-426.
28. Batiuk TD, Kung L, Halloran PF Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997, 100:1894-1901.
29. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
30. Venkataramanan R, Jain A, Warty VW, Abu-Elmagd K, Furakawa H, et al. Pharmacokinetics of FK 506 following oral administration: A comparison of FK506 and cyclosporine. Transplant Proc 1991, 23:931-933.
31. Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: Twice daily versus once daily dosing. Am J Transplant 2004, 4:621-625.
32. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810.
33. Woodward RS, Kutinova A, Schnitzler MA, Brennan DC Renal graft survival and calcineurin inhibitor. Transplant 2005, 80:629-633.
34. Goldfarb-Rumyantzev AS, Smith L, Shihab FS, et al. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 2006, 1:563.
35. Tedesco-Silva A, Demirbas S, Vitko B, Nashan A, Gurkan R, et al. Symphony: Comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Transplant 2006, 82:83.
36. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002, 7:141-149.
37. Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, et al. Four-year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005, 9:498-503.
38. Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study. Pediatr Transplant 2003, 7:217-222.
39. Tanabe K Calcineurin inhibitors in renal transplantation: what is the best option?. Drugs 2003, 3:1535-1548.
40. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJT, Allen RD, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326-2333.
41. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940.
42. Toenshoff B, Hoecker B Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant 2006, 10:721-729.
43. Oellerich M, Armstrong VW Two-hour cyclosporine concentration determination: An appropriate tool to monitor neoral therapy?. Ther DrugMonit 2002, 24:40-46.
44. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplant 1999, 68:1356-1361.
45. Kyllonen LE, Salmela KT Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplant 2006, 81:1010-1015.
46. Weber LT, Armstrong VW, Shipkova M, Feneberg R, Wiesel M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004, 26:415-424. for Members of the German Study Group on Pediatric Renal Transplantion.
47. Gaston RS Maintenance immunosuppression in the renal transplant recipient: An overview. Am J Kidney Dis 2001, 38:25-35.
48. Elion GB The pharmacology of azathioprine. Ann NY Acad Sci 1993, 685:400-407.
49. Bergan S, Rugstad HE, Bentdal O, Sodal G, Hartmann A, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplant 1998, 66:334-339.
50. Allison AC, Eugui EM Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplant 2005, 80:181-190.
51. van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. Cardiovasc Res 2006, 69:341-347.
52. van Gelder T, Tedesco Silva H, de Fijter H, Budde K, Kuypers D, et al: A prospective, randomized, open-label, multicenter study comparing fixed-dose versus concentration-controlled mycophenolate mofetil regimens for de novo renal transplant recipients: The Fixed-Dose Concentration-Controlled (FDCC) trial, Transplantation, in press.
53. Shipkova M, Armstrong VW, Oellerich M, Wieland E Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005, 1:505-526.
54. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
55. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998, 9:1511-1520. For the German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
56. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 2002, 13:759-768.
57. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplant 2005, 80:11-20.
58. Ettenger R, Cohen A, Nast C, et al. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997, 29:340-341.
59. Benfield MR, Symons JM, Bynon S, et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999, 3:5-9.
60. Bunchman T, Navarro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001, 16:978-984.
61. Hoecker B, Weber LT, Bunchman T, Rashford M, Toenshoff B Mycophenolate mofetil suspension in pediatric renal transplantation: Three-year data from the tricontinental trial. Pediatr Transplant 2005, 9:504-511. for the Tricontinental MMF Suspension Study Group.
62. Staskewitz A, Kirste G, Tönshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment. Transplant 2001, 71:638-644. for the German Pediatric Renal Transplantation Study Group.
63. Jungraithmayr T, Staskewitz A, Kirste G, et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: Results after three years. Transplant 2003, 75:454-461.
64. Cransberg K, Marlies Cornelissen EA, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands: Effect of the introduction of mycophenolate mofetil?. Pediatr Transplant 2005, 9:104-111.
65. Ferraris JR, Ghezzi LF, Vallejo G, et al. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005, 9:178-182.
66. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplant 2001, 72:77-83.
67. Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplant 2003, 76:1326-1330.
68. Van Gelder T, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
69. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplant 1999, 68:261-266.
70. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Toenshoff B Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006, 28:623-631.
71. Filler G, Mai I Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000, 22:169-173.
72. Kahan BD, Camardo JS Rapamycin: Clinical results and future opportunities. Transplant 2001, 72:1181-1193.
73. Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001, 72:851-855.
74. MacDonald A, Scarola J, Burke JT, Zimmerman JJ Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000, 22(B):B101-B121.
75. Gatta del Mar Fernandez De, Santos-Buelga D, Dominguez-Gil A, Garcia MJ Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 2002, 41:115-135.
76. Ettenger RB, Grimm EM Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001, 38:S22-S28.
77. Mahalati K, Kahan BD Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001, 40:573-585.
78. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000, 14:97-109.
79. Kuypers DR Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005, 28:153-181.
80. Hocker B, Feneberg R, Kopf S, Weber LT, Waldherr R, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006, 10:593-601.
81. Ettenger R, Sarwal MM Mycophenolate mofetil in pediatric renal transplantation. Transplant 2005, 80(2):S201-S210.